Introduction
============

The benefits of glycemic control on reducing the risk for microvascular complications are now quite well established from both observational data sets and intervention trials ([@b7], [@b8]; [@b9]; [@b52],[@b53]). Several factors limit the ability to normalize blood sugar in diabetic patients. These include the inability to target each of the pathophysiological defects associated with hyperglycemia, side effects of medication, contraindications to use of selected medications (eg, renal dysfunction, heart failure), risks for hypoglycemia, and the common association of intensive glycemic control with a risk for weight gain. This article will focus on the use of pramlintide, a synthetic version of amylin (a glucose lowering hormone) and its role in the management of diabetes. Pramlintide targets mainly postprandial glycemic excursion, and as such the effects on mean glycemic control as determined by HbA1c are modest. However, there are very few contraindications, hypoglycemia risk is low, and absence of weight gain (or even weight loss) typifies its use. This article will review the development of pramlintide, its use in diabetes mellitus (DM) as a glycemic control agent, and its effects on body weight as well as current limited data on blood pressure, lipids, and some oxidation biomarkers that are associated with cardiovascular disease risk.

Amylin physiology and pathophysiology
=====================================

Amylin is a 37 amino acid polypeptide that is co-secreted in equimolar quantities with insulin from pancreatic β cells ([@b54]; [@b62]). Of note is the fact that amylin secretion is diminished (or even absent) in patients with types 1 and 2 diabetes ([@b2]). Furthermore, the degree of insulin deficiency generally correlates with the degree of amylin deficiency ([@b62]). Amylin is metabolized by proteolytic degradation in the kidney ([@b62]).

Amylin has glucose-lowering effects in both animals and humans. [@b54] have summarized the effects (with their corresponding extensive references) as follows: (1) suppression of endogenous glucagon production, especially in the postprandial state; (2) consequent reduction of postprandial hepatic glucose production; (3) reduction in gastric emptying time; (4) centrally mediated induction of satiety; and (5) reduction in postprandial glucose levels.

Because native amylin was characterized as "glue like," somewhat unstable as a compound in solution, modifying amylin to a compound with more manageable physical properties resulted in the development of pramlintide. Pramlintide has similar physiologic effects as native amylin (see [Table 1](#tbl1){ref-type="table"}), but could be produced as the stable injectible product now available for clinical use as Symlin™ ([@b50]; [@b55]; [@b29]). Physiologic effects of native amylin and the synthetic analogue, pramlintide, include suppression of postprandial glucagon and slowing of gastric emptying. Insulin deficiency and glucagon excess have both been shown to contribute to postprandial glycemic excursion ([@b47]). Thus the effects of pramlintide on postprandial glycemic control appear to be at least partially mediated by restoring appropriate prandial reduction in glucagon ([@b15]; [@b13], [@b12]; [@b33]; [@b22]). It does not appear that this prandial suppression of glucagon by pramlintide impedes the glucagon response to hypoglycemia. Amiel evaluated each of the counter-regulatory hormones triggered by hypoglycemia (catecholamines, growth hormone, cortisol, and glucagon) and found that pramlintide administration did not attenuate the effects of any of them, including glucagon ([@b1]).

###### 

Summary characteristics of amylin and pramlintide

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Amylin**
  37 amino acid compound
  Co-secreted with insulin from beta cells
  Deficient in type 1 and type 2 DM
  Renal clearance
  Physiological effects Suppression of endogenous glucagon production (especially in the postprandial state)Reduction in postprandial hepatic glucose productionReduction in gastric emptying timeCentrally mediated induction of satietyReduction in postprandial glucose levels
  **Pramlintide**
  Synthetic analogue of amylin (3 amino acid substitutions with proline for
  native amino acids
  Subcutaneous administration
  Effects in type 1 and type 2 DM Reduction in prandial glucoseReduction in HgbA1cReduction in prandial glucagonsSlowed gastric emptyingWeight loss
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Glycemic control in diabetes mellitus
=====================================

Pramlintide use in type 1 DM
----------------------------

The preprandial administration of pramlintide as an adjunct to preprandial insulin therapy leads to a substantial reduction in postprandial hyperglycemia ([@b30], [@b31]; [@b49],[@b48]; [@b39]; [@b60]; [@b59]; [@b22]; [@b26]) as a result of suppressing postprandial hyperglucagonemia ([@b39]; [@b60]; [@b14]) as well as delaying gastric emptying ([@b32]; [@b55]). Clinical studies have shown that reduction in postprandial glucose excursion translates into significant and sustained reductions in HbA1c (see [Table 2](#tbl2){ref-type="table"}) ([@b11]; [@b18]; [@b61]; [@b42]; [@b10]). In a multicenter study of 480 patients with type 1 DM, Whitehouse and colleagues showed that treatment with pramlintide led to a mean reduction in HbA1c of 0.67% from baseline to week 13 that was significantly (p \< 0.0001) greater than the placebo reduction (0.16%); a significant placebo-corrected treatment difference was sustained through week 52 (p = 0.007) ([@b61]). This was not accompanied by an increased overall event rate of severe hypoglycemia. Ratner and colleagues showed that the addition of pramlintide 60 μg 3 times daily (tid) or 4 times daily (qid) to insulin led to significant reductions in HbA1c of 0.29% (p \< 0.011) and 0.34% (p \< 0.001) respectively, compared with a 0.04% reduction in placebo group, over 52 weeks ([@b42]). In this study, the proportion of pramlintide vs placebo-treated patients who achieved an HbA1c of \<7% was 3-fold higher. This was achieved without an increase in concomitant insulin use in the pramlintide-treated group. In a subset of these patients combined with patients from other studies in whom HbA1c values were \<8.0% at entry, favorable effects on glycemic control were also demonstrated ([@b41]).

###### 

Studies of pramlintide use in patients with type 1 DM

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study      Patients (n)   Study design          Duration (weeks)   Pramlintide dose                        HbA1c Δ(%)                 Wt (kg)
  ---------- -------------- --------------------- ------------------ --------------------------------------- -------------------------- ---------------------------------------
  ([@b11])   586            DB, PC, multicenter   26                 60 μg tid or 90 μg bid-tid or placebo   −0.2 (p = sign.)\          −1.6\
                                                                                                             −0.1 (NS)\                 −0.7\
                                                                                                             −0.1 (NS)\                 −1.6\
                                                                                                             +0.1                       +0.3\
                                                                                                                                        (NS)

  ([@b18])   479            DB, PC, multicenter   52                 60 μg tid-qid or placebo                −0.4/−0.3\                 −1.4/−1.7\
                                                                                                             NR\                        NR\
                                                                                                             (p = sign.)                (p = sign.)

  ([@b61])   480            DB, PC, multicenter   52                 30−60 μg qid or placebo                 −0.39\                     −0.5[a](#tf1-1){ref-type="table-fn"}\
                                                                                                             −0.12\                     +1.0[a](#tf1-1){ref-type="table-fn"}\
                                                                                                             (p = 0.0071)               (p \< 0.001)

  ([@b42])   479            DB, PC, multicenter   52                 60 μg tid-qid or placebo                −0.29/−0.34\               −0.4/−0.4\
                                                                                                             −0.04\                     +0.8\
                                                                                                             (p \< 0.011 and \<0.001)   (p \< 0.027 and \<0.040)

  ([@b10])   296            DB, PC, multicenter   29                 30--60 μg tid or placebo                −0.5\                      −1.3\
                                                                                                             −0.5                       +1.2\
                                                                                                                                        (p \< 0.0001)
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------

These data were extrapolated from graphs, because the absolute values were not reported in the test of the published studies.

**Note:** Fineman 1999, [@b61], [@b42] studies − subjects with entry HbA1c between 7.0 and 8.5% (n = 477) are summarized in [@b41].

**Abbreviations:** DB, double-blind; MC, multicenter; PC, placebo-controlled; R, randomized; RCT, randomized control trials.

Several studies have assessed the effect of pramlintide on weight control in patients with type 1 DM. In the study reported by Whitehouse, the greater HbA1c reduction in the pramlintide-treated group was associated with an average weight loss (rather than commonly observed weight gain with improved glycemic control). Weight loss was significant from week 13 onward ([@b61]). Ratner also reported that greater reduction in HbA1c with pramlintide was accompanied by a significant reduction in body weight from baseline to week 52 of 0.4 kg in the 60 μg tid (p \< 0.027) or qid (p \< 0.040) pramlintide treatment groups, compared with a 0.8 kg gain in body weight in the placebo group ([@b42]). A 29-week, double-blind, randomized, placebo-controlled study of 296 patients with type 1 DM showed that pramlintide treatment significantly reduced weight (pramlintide −1.3 ± 0.30, placebo +1.2 ± 0.30 kg; p \< 0.0001) despite equivalent HbA1c reductions relative to placebo ([@b10]).

The most commonly reported adverse effects associated with pramlintide use in type 1 DM were nausea, anorexia, and hypoglycemia in these studies. These adverse effects occurred more often during the initiation of therapy and were usually mild to moderate in nature ([@b60]; [@b61]; [@b42], [@b41]; [@b45]; [@b10]; [@b38]). Pramlintide treatment improved patient satisfaction in some studies despite requiring additional injections ([@b56]; [@b35]).

Pramlintide use in type 2 DM
----------------------------

In type 2 DM pramlintide has been approved for use as an adjunct to preprandial insulin with or without concurrent metformin or sulfonylurea therapy in patients with sub-optimal glucose control. This approval was based on the ability of pramlintide to improve glucose control when added to insulin therapy and has been supported by both short and long term studies ([@b41], [@b43]; [@b61]; [@b24], [@b23]; [@b19]) (see [Table 3](#tbl3){ref-type="table"}). Ratner conducted a multi-centre randomized clinical trial (RCT) of 1 year duration and showed that addition of pramlintide to meal time insulin resulted in a reduction in a mean HbA1c of 1% by 13 weeks at the 150 μg dose ([@b43]). This effect was sustained at the end of 1 year with a mean reduction of HbA1c by 0.6% in both treatment arms (75 μg, 120 μg) compared with the placebo arm. Another study in type 2 DM demonstrated a similar sustained reduction in A1c of 0.62% at the 120 μg dose as compared to placebo (p \< 0.05) ([@b25]). In both long-term studies, a significantly greater proportion of patient in the treatment arm were able to achieve a target HbA1c of \<8%. A pooled post-hoc analysis of 2 large RTC of approximately 500 patients showed that treatment of pramlintide with 120 μg bid demonstrated a significant placebo-corrected reduction of HbA1c of 0.41% at 26 weeks (p \< 0.0001) ([@b23]). In a study similar to the analysis in type 1 DM ([@b41]), Hollander also reported favorable glycemic effects in type 2 DM patients who were close to recommended glycemic targets ([@b24]). In these studies patients using pramlintide needed proportionally lower doses of total daily insulin. As demonstrated in the studies of type 1 DM, pramlintide does not require β cell function to exhibit its full glucose lowering effect. Therefore, it is can also be used in a population with advanced type 2 DM who have reduced β cell function.

###### 

Studies of pramlintide use in patients with type 2 DM

  Study                                      Pat (n)   Study design                                                 Duration (weeks)   Pramlintide dose     ΔHbA1c (%)                                                               ΔWeight (kg)
  ------------------------------------------ --------- ------------------------------------------------------------ ------------------ -------------------- ------------------------------------------------------------------------ ---------------------------------------------------------------------------
  ([@b50])                                   203       MC, R, DB, PC                                                4                  Placebo              −0.27                                                                    **−0.04**
                                                                                                                                       30 μg qid            −0.53[\*](#tf3-5){ref-type="table-fn"}                                   **−0.36**
                                                                                                                                       60 μg tid            −0.58[\*](#tf3-5){ref-type="table-fn"}                                   **−0.89**[\*\*](#tf3-6){ref-type="table-fn"}
                                                                                                                                       60 μg qid            −0.51[\*](#tf3-5){ref-type="table-fn"}                                   **−0.72**[\*\*](#tf3-6){ref-type="table-fn"}
  ([@b19])                                   499       MC, DB, PC                                                   26                 Placebo              −0.1                                                                     **0.1**
                                                                                                                                       90 μg bid            −0.3                                                                     **−0.8**
                                                                                                                                       90 μg tid            −0.4                                                                     **−1.3**
                                                                                                                                       120 μg bid           −0.4[\*](#tf3-5){ref-type="table-fn"}                                    **−1.4**
  ([@b41])                                   538       MC, R, DB, PC                                                52                 Placebo              −0.2[c](#tf3-3){ref-type="table-fn"}                                     **1.0**[c](#tf3-3){ref-type="table-fn"}
                                                                                                                                       30 μg tid            −0.3[c](#tf3-3){ref-type="table-fn"}                                     **−0.3**[c](#tf3-3){ref-type="table-fn"}
                                                                                                                                       75 μg tid            −0.5[c](#tf3-3){ref-type="table-fn"}                                     **−0.4**[\*](#tf3-5){ref-type="table-fn"}[c](#tf3-3){ref-type="table-fn"}
                                                                                                                                       150 μg td            −0.6[\*](#tf3-5){ref-type="table-fn"},[c](#tf3-3){ref-type="table-fn"}   **−1.2**[\*](#tf3-5){ref-type="table-fn"}[c](#tf3-3){ref-type="table-fn"}
  ([@b25])[a](#tf1-1){ref-type="table-fn"}   656       MC, R, DB, PC                                                52                 Placebo              −0.25[c](#tf3-3){ref-type="table-fn"}                                    **+0.7**
                                                                                                                                       60 μg tid            − [b](#tf3-2){ref-type="table-fn"}                                       **−**[b](#tf3-2){ref-type="table-fn"}
                                                                                                                                       90 μg bid            −0.35                                                                    **−0.5**
                                                                                                                                       120 μg bid           −0.62[\*](#tf3-5){ref-type="table-fn"}                                   **−1.4**[\*](#tf3-5){ref-type="table-fn"}
  ([@b23])                                   498       Post hoc analysis of 2 RCT[d](#tf3-4){ref-type="table-fn"}   26                 Placebo 120 μg bid   −0.41[\*\*\*](#tf3-7){ref-type="table-fn"}                               **−1.8**[\*\*\*](#tf3-7){ref-type="table-fn"}

Subset of this population with lower HbA1c values also published ([@b24]).

Excluded after efficacy analyses after results from another study (not identified) indicated that this dose was less effective.

These data were extrapolated from graphs, because the absolute values were not reported in the test of the published studies.

Gottlieb et al (1999), [@b23].

p \< 0.05;

p \< 0.01;

p \< 0.0001.

**Abbreviations:** DB, double-blind; MC, multicenter; PC, placebo-controlled; R, randomized; RCT, randomized control trials.

Effect on body weight
=====================

Improvement in glycemic control and associated increase in body weight is well-known ([@b40]; [@b26]). In UKPDS, weight gain was noted to be greater in the intensive policy group compared to the conventional policy group ([@b52],[@b53]) and occurred not only with insulin and sulphonylureas but also with metformin. Participants in the conventional policy group also gained weight. The gain occurred in all groups despite patients receiving dietary advice from a dietitian to maintain a near normal weight. In fact the dietary efforts, including recommendation for a calorie- restricted diet, were implemented 3 months prior to randomization and were continued throughout the trial. This implies that dietary modification, albeit very important, is not sufficient to limit weight gain. Weight gain is a well known barrier to the treatment of type 2 DM, especially in patients who are overweight or obese. Such patients may actually avoid achieving glycemic target to prevent accrual of additional pounds. The etiology of weight gain with improved glycemic control is likely to be multi faceted -- reduction in glucosuria, increased caloric intake to avoid hypoglycemia, and anabolic effect of insulin on adipose tissue ([@b40]). It has been estimated that patients gain about 2 kg (4.4 lbs) for every 1% reduction in Hba1c ([@b40]).

The addition of pramlintide to adjuvant insulin causes weight loss in a majority of people. Of note, the initial studies were not designed to be weight loss trials. But a post-hoc analysis involving 2 large studies that included over 240 patients in each arm showed a placebo corrected reduction in body weight of 0.41% and 1.8 kg (p \< 0.0001) ([@b23]). Weight loss is moderate in overweight and moderately obese patients and occurs in spite of a reduction in HbA1c. This is in striking contrast to weight gain with intensification of insulin therapy. Weight loss is more pronounced in patients with severe obesity and occurs regardless of whether patients experience nausea, confirming the notion that the weight reduction is not simply a secondary consequence of nausea. Hollander also noted that pramlintide seemed to have somewhat greater weight lowering effect in patients concomitantly treated with metformin (placebo-corrected treatment difference at week 26: −2.5 vs 1.6 kg in subjects not concomitantly treated with metformin), but the authors advise caution in the interpretation of the results because of the relatively small sample size and the post-hoc nature of the analyses ([@b23]).

Weight control/loss mechanisms and studies
------------------------------------------

The exact mechanism of amylin mediated weight loss remains undefined. In rodents, amylin has been shown to dose dependently reduce food intake and body weight by affecting the size and duration of meals. This mechanism appears to be centrally mediated and is independent of gastric emptying ([@b34]; [@b60]; [@b46]). High density amylin sites have been identified in the dorsal raphe and nucleus acumbens, two brain regions that control feeding behavior ([@b60]).

Pramlintide's effect on appetite targets peripheral episodic satiety signals ([@b20]) and as such is similar to glucagon-like peptide analogues and peptide YY analogues. There is evidence of a satiety effect in both rodents, diabetic and non-diabetic human subjects. Chapman et al studied 16 diabetic and 14 non-diabetic men to determine the effects of pramlintide administration (compared to placebo) on satiety and caloric intake from an available buffet meal ([@b6]). Pramlintide was associated with earlier satiety and reduced food intake. As noted above Hollander has reported weight loss with pramlintide administration in obese type 2 diabetes patients ([@b24], [@b23]; [@b6]). In an observational study, Want reported on glycemic control and weight changes in 27 subjects with type 2 DM followed for several years ([@b57]). Subjects whose baseline body mass index (BMI) was \>25 kg/m^2^ lost an average of 4 kg.

Biomarkers of cardiovascular disease
====================================

There are only a few studies that have reported on the effects of pramlintide on risk factors known or suspected to be associated with cardiovascular disease. The favorable effects on appetite and weight reduction suggest that there should be consistent effects on blood pressure reduction, dyslipidemia, and inflammatory/oxidation markers. It should be noted that while there is a large body of evidence suggesting that replacement of amylin with pramlintide in patients with diabetes provides significant clinical benefits, more studies are needed to assess the effect of pramlintide on complications of diabetes. What follows has been reported with amylin and/or pramlintide use.

Blood pressure
--------------

Native amylin has been associated with hypertension in 283 hypertensive patients reported by Kailisam et al (2000). These authors concluded that increased concentrations of amylin seen in hypertensive patients might be genetically mediated rather than assuming any causal relationship. In a letter to *Diabetologia*, Young reported blood pressure results in 507 type 2 diabetic subjects with pramlintide use showing no differences in systolic or diastolic blood pressure in the 3 treatment groups (30, 75, or 150 μg tid) compared to placebo or any change from baseline during 1 year of treatment ([@b63]). It does not appear that hypertension has characterized pramlintide use in the RCTs. Neither hypertension nor marked hypotension are common in clinical practice with pramlintide use. At present it does not appear that pramlintide has any significant effect on blood pressure.

Lipids
------

Thomson has reported on lipid values in 203 type 2 diabetic subjects treated with placebo and three different doses of pramlintide (30 μg QID; 60 μg TID; 60 μg QID) over a period of 4 weeks in a randomized, double blind trial ([@b50]). Median reductions in total cholesterol for the four groups were 0 mg/dL, 9 mg/dL, 9 mg/dL, and 14 mg/dL respectively. The median reduction in the three pramlintide treatment groups was statistically different from baseline. Median LDL changes in the 60 μg tid and 60 μg qid were 8 mg/dL and 10 mg/dL, respectively. These differences also reached statistical significance. However, mean changes for the treatment groups were not different than placebo although mean percent changes suggest a dose response relationship for total cholesterol, LDL cholesterol, and triglycerides ([Figure 1](#fig1){ref-type="fig"}). Levetan studied 16 patients with type 1 DM and showed that after 4 weeks of pramlintide therapy reductions of postprandial glucose excursion by 86% and glucagon excursion by 87% were associated with a reduction of triglyceride excursion by 72% ([@b33]). Effects of pramlintide on lipids seem modest. Analyses of lipids in subsets of patients who have lost significant amounts of weight have not been published, so it is not clear if these will parallel the observations reported with exenatide ([@b3]).

![Mean percent changes in lipid values in 203 type 2 diabetic patients on placebo and 3 different doses of pramlintide for 4 weeks. Derived from [@b50].](vhrm0402-355-01){#fig1}

Markers of oxidation
--------------------

Oxidized lipoproteins, especially oxidized LDL and down-stream oxidation products of myeloperoxidase such as dinitrotyrosine have been associated with increased risk for cardiovascular disease ([@b21]; [@b48]; [@b36], [@b37]). Oxidation has also been implicated in the pathogenesis of diabetic microvascular complications ([@b17]; [@b5], [@b4]). Pramlintide use has also been associated with a significant reduction in postprandial markers of oxidative stress including significantly reduced postprandial excursions of glucose, nitrotyrosine, and oxidized LDL. Pramlintide also prevented a decline in total radical-trapping antioxidant parameter (using the method reported by Ghiselli called TRAP ([@b16]) as compared with placebo (p \< 0.03). These changes correlated with reduction in postprandial glycemic control.

Practical considerations
========================

Pramlintide has efficacy when used in conjunction with preprandial insulin therapy in both type 1 and type 2 DM. There is generally a need to reduce insulin requirements when pramlintide is initiated. The reduction in insulin is usually in the range of 20% to 50% of preprandial doses ([@b45]; [@b56]). This adjustment is affected by the individual patient's levels of glycemic control. In patients who are generally well controlled and in whom the use of pramlintide is not only used to reduce prandial glycemic excursion but also to facilitate weight loss, 50% reductions in preprandial insulin are advisable. In patients with overall suboptimal glycemic control, then continuation of preprandial insulin with only small reductions in dose work well. In any case patients need to be warned about the increased risk for postprandial hypoglycemia (there is a "black box" warning in the package insert) with typical risk occurring for about 3 hours after the meal ([@b27]). All patients, especially those with a history of hypoglycemia, need to be instructed to increase the frequency of glucose monitoring to detect hypoglycemia. It is important to note that pramlintide does not impair the glucagon response to hypoglycemia.

Our experience indicates that initiation of pramlintide therapy requires careful instruction even in patients who have taken insulin for extended periods of time. The concept that a 15 μg dose corresponds to 2.5 units on an insulin syringe intuitively seems to be an easy concept. The instructions provided with the pramlinitide patient kits review syringe related administration in detail. However, review of dosing administration by a diabetes educator is advisable. Furthermore, many patients have become used to the ease of dosing with insulin delivered via pen. Pramlintide has recently become available in pen delivery devices. Each of these devices has predetermined dosing for pramlintide of 15, 30, 60, and 120 μg. These pens should simplify pramlintide administration.

Want and Ratner have proposed a dose titration in type 2 diabetes which they report is easier for patients to follow ([@b57]). Patients with type 1 DM begin with 12 μg (2 units on insulin syringe) ac and increase by 6 μg (1 unit) every 3--7 days until they reach the target dose of 60 μg. Similarly patients with type 2 diabetes begin with 24 μg (4 units) and increase by 12 μg (2 units) until they reach the target dose of 120 μg ac. This approach helps to simplify instructions with pramlintide vial usage.

One common question raised by patients is whether pramlintide can be mixed with insulin so that they can give a single injection. Although small short-term studies suggest that mixing with insulin does not affect efficacy ([@b58]), pramlintide is not approved for use when mixed with insulin and we routinely recommend giving it as a separate injection. The small volume (0.2 mL even with the 120 μg dose) is not prohibitive for most patients. Pramlintide pens have recently become available which will make dosage instruction and administration easier.

Nausea is common with initiation of therapy. Starting therapy with low dose (15 μg ac in type 1 DM and 30 μg ac in type 2 DM) reduces the risk for nausea. However, our experience indicates that a small percentage of subjects have intolerable nausea even at low doses. This may be a central effect. Nausea is also likely to be more of a problem in patients with gastroparesis, which could be made worse by any agent affecting gastric emptying. However, pramlintide is generally considered to be contraindicated in patients with gastroparesis ([@b27]) or in patients who are on other agents known to have effects on gastric emptying such as the alpha glucosidase inhibitors. Except in rare cases, nausea usually remits with continued use. Pramlintide has not been approved for use in pregnancy as safety in pregnancy has not been established.

Pramlintide's use in the immediate future will continue to be as a tool for glycemic control. Future considerations are likely to include monotherapy or as an adjunct to other medications being developed for weight loss. This potential use in weight loss is based on early studies in rodent models ([@b44]). Recently, Amylin reported the following on their web site: "...positive results from a 24-week proof-of-concept study with pramlintide, an analog of human amylin, and recombinant human leptin (r-metHuLeptin; metreleptin) combination treatment in overweight or obese subjects. At study end, pramlintide/metreleptin treatment reduced body weight on average by 12.75%, significantly more than treatment with pramlintide alone (8.4%; p \< 0.001)." (<http://investors.amylin.com/phoenix.zhtml>). In spite of these observations, the long-term effects of pramlintide on weight are not known.
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